You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The new funding supports development of a rapid molecular test to detect bloodstream infections directly from whole blood.
The legislation is intended to allow states to conduct whole-genome sequencing on children on Medicaid who have a disease with a suspected genetic cause.
By identifying core venom toxin genes with Indian cobra genomic and transcriptomic data, researchers hope to set the stage for future antivenom production based on synthetic venom.
The new firm will offer target enrichment assays for clinical NGS testing and develop library preparation kits for clinical tests on Illumina's sequencing platform.
As part of the collaboration, UNC will use the firm's BarreGen assay to target molecular changes to predict resistance or relapse following ablation.
A federal court said Guardant CEO Helmy Eltoukhy deleted emails pertaining to two similar cases, but it remains unclear whether he did so intentionally.
Last week, GenomeWeb's readers were most interested in the termination of the merger agreement between Illumina and Pacific Biosciences.
The index's gain was well above the 13 percent increase of 2018, and almost reached the 39 percent increase it saw in 2017.
News items for the week of Dec. 30, 2018.
The company will use the proceeds to strengthen its balance sheet and support the commercial launch of new products and development activities over the coming year.
Illumina will pay Pacific Biosciences a termination fee of $98 million, in accordance with the merger agreement, originally announced in November 2018.
The LCD for the RNA gene expression test will take effect on Feb. 10, 2020, the Medicare contractor said.
The GenomeWeb Index vastly outperformed the Dow Jones and the Nasdaq Biotechnology Index this month, while slightly underperforming the Nasdaq.
The UK-based sequencing technology firm raised £29.3 million in capital and sold £80.2 million in secondary shares.
The approval will allow clinicians to identify NSCLC patients with ROS1 fusion genes who could benefit from treatment with Rozlytrek.
The investment bank gave PerkinElmer an Outperform rating with a $114 stock price target and Hologic an In Line rating with a $55 stock price target.
A Sun-Yat Sen University Cancer Center-led team found circulating tumor DNA methylation patterns could detect colorectal cancer among asymptomatic individuals.
A team led by researchers at the Chinese University of Hong Kong found that extrachromosomal circular DNA of fetal origin is smaller than that of maternal origin.
The investment banking firm has lowered its rating for shares of the sequencing giant, but raised its price target to $340 from $330.
Within the master observational trial, the organizations have agreed to prospectively collect real world data and ultimately build a national oncology database.
The drug is approved as a maintenance treatment for platinum-responsive metastatic pancreatic cancer patients with germline BRCA1/2 mutations.
The firm had received interest from unnamed potential acquisition partners following the departure of its CEO, but it has decided to remain as a standalone business.
Roche will pay Codexis royalties under a worldwide license to include EvoT4 DNA ligase in next-generation sequencing products and workflows.
Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.
Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.
The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.
In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.